Search Here

Novo Nordisk has ended its partnership with telehealth company Hims & Hers Health, pulling its popular weight-loss drug Wegovy from the platform.

The decision comes after Novo Nordisk raised serious concerns, accusing the company of offering unapproved and potentially unsafe versions of the drug—something the drugmaker says could put patients in danger.

According to CBS News, in a public statement, Novo Nordisk said Hims & Hers had failed to follow US drug safety laws, particularly around the marketing and sale of compounded drugs. "This is unacceptable," a Novo Nordisk spokesperson stated.

"They have engaged in deceptive marketing and sold knock-off versions of Wegovy under the false promise of 'personalization.'"

The announcement caused shares of Hims & Hers to fall by more than 30% on Monday. The company has not yet responded publicly to the decision.

Wegovy, a GLP-1 drug approved by the FDA in March 2024 for adults with obesity, has been in high demand.

Novo Nordisk began working with telehealth companies to make the medication more accessible, especially after the US faced a nationwide shortage earlier this year.

Novo Nordisk Warns of Unsafe Knock-Off Wegovy From China

Part of that effort involved steering patients away from unauthorized compounded versions of Wegovy being sold by some pharmacies and platforms.

Novo Nordisk claims many of these versions are made using unverified ingredients from suppliers in China that have not been approved or inspected by the FDA, PR Newswire said.

"US patients should not be exposed to knock-off drugs made with unsafe and illicit foreign ingredients," the company stated.

According to their internal investigation, some of the semaglutide used in these versions lacked proper FDA oversight and were produced in facilities with known drug quality violations.

Novo Nordisk said it would continue to offer Wegovy through other trusted telehealth companies like LifeMD and Ro—providers they say share their commitment to safety and legal compliance.

Dave Moore, Executive Vice President of US Operations at Novo Nordisk, added, "We are firm in our mission to protect patients living with obesity.

When people are prescribed Wegovy, they deserve access to the real, FDA-approved medication—not unregulated, unsafe alternatives."

Hims & Hers had previously predicted strong revenue from weight-loss products this year, but the loss of Wegovy may challenge those projections.

Tags

Novo Nordisk